An interventional study of Delayed Dental Implant Placement and Advanced Platelet-Rich Fibrin (A-PRF) in Partial Edentulism and Dental Implant Placement, sponsored by Samar Ali Abdu Salamah. Recruiting at 1 site in Yemen. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-02.
Sponsored by Samar Ali Abdu Salamah · Not applicable, Interventional, and Treatment
This randomized parallel-group clinical trial aimed to evaluate the clinical efficacy of advanced platelet-rich fibrin (A-PRF) combined with hyaluronic acid (HA) in enhancing peri-implant bone formation in patients undergoing delayed dental implant placement. Participants will be allocated to either a test group, in which A-PRF combined with HA is applied at the implant site, or a control group receiving conventional implant placement without adjunctive biomaterials. Peri-implant bone changes will be assessed using cone-beam computed tomography (CBCT), including radiographic bone density and bone volume measurements. Implant stability will also be evaluated using resonance frequency analysis at the time of implant placement and during follow-up. Additional clinical outcomes include postoperative pain and implant survival. The participants will be followed up for six months after implant placement.
This is the only study on the registry with Samar Ali Abdu Salamah as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Adults aged 18-65 years.
Patients requiring delayed dental implant placement in a posterior mandibular edentulous site
Sufficient residual alveolar bone height and width to permit conventional implant placement without the need for simultaneous guided bone regeneration (GBR), ridge augmentation, or other bone-grafting procedures.
Good general health or a medically controlled and stable systemic condition compatible with elective implant surgery and not expected to materially compromise wound or bone healing.
Non-smokers with no current use of tobacco products.
Acceptable oral hygiene and a periodontal condition compatible with implant surgery following any required professional treatment and reassessment.
Ability and willingness to undergo the required clinical and radiographic assessments, including CBCT examinations at baseline and at the 6-month follow-up.
Ability and willingness to attend the scheduled follow-up visits and comply with the study procedures.
Provision of written before study participation.
Exclusion Criteria:
-
Any uncontrolled systemic disease or medical condition that conensions for conventional implant placement without augmentation.
Requirement for immediate implant placement, simultaneous guided bone regeneration, ridge augmentation, or any other adjunctive bone-grafting procedure.
Inability or unwillingness to complete the required 6-month clinical and radiographic follow-up.traindicates elective implant surgery or may substantially impair wound or bone healing, including uncontrolled diabetes mellitus.
status or current systemic immunosuppressive therapy.
Current or previous use of oral or parenteral bisphosphonates or other antiresorptive medications associated with a risk of medication-related osteonecrosis of the jaw.
Pregnancy at the time of screening or enrollment.
Unresolved active periodontal disease or active local infection involving the intended implant site, including suppuration.
Inadequate oral hygiene that persists after professional oral-hygiene instruction, necessary periodontal treatment, and reassessment.
Insufficient residual alveolar bone dim
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive delayed dental implant placement with adjunctive application of advanced platelet-rich fibrin (A-PRF) combined with hyaluronic acid at the implant site.
Procedure: Delayed Dental Implant Placement · Procedure: Advanced Platelet-Rich Fibrin (A-PRF) · Device: Hyaluronic Acid 1.5%
Participants receive delayed dental implant placement without adjunctive A-PRF or hyaluronic acid.
Procedure: Delayed Dental Implant Placement
A dental implant was surgically placed into a healed edentulous site using a standardized delayed-placement protocol. This procedure was performed in both the test and control groups.
Autologous advanced platelet-rich fibrin (A-PRF) was prepared from the participants' venous blood using a standardized centrifugation protocol and applied at the dental implant site. In the test group, A-PRF was used in combination with hyaluronic acid as an adjunct to delayed dental implant placement.
In the test group, 1.5% hyaluronic acid is combined with autologous advanced platelet-rich fibrin (A-PRF) and applied locally at the dental implant site during delayed dental implant placement. The control group does not receive hyaluronic acid.
CBCT-Derived Peri-Implant Bone Volume
The peri-implant bone volume will be assessed using cone-beam computed tomography (CBCT) at baseline and 6 months after dental implant placement. Changes in bone volume between baseline and the 6-month follow-up will be evaluated and compared between the test and control groups.
Time frame: Baseline and 6 months after implant placement
CBCT-Derived Peri-Implant Radiographic Density
Peri-implant radiographic density will be assessed using cone-beam computed tomography (CBCT) at baseline and 6 months after dental implant placement. Changes in radiographic density between baseline and the 6-month follow-up will be evaluated and compared between the test and control groups.
Time frame: Baseline and 6 months after implant placement
Implant Stability Quotient (ISQ)
Implant stability will be assessed using resonance frequency analysis and expressed as Implant Stability Quotient (ISQ) values. ISQ will be measured at the time of implant placement and at the 6-month follow-up, and changes will be compared between the test and control groups.
Time frame: At implant placement and 6 months after implant placement
Dental Implant Survival Rate at 6 Months
Implant survival will be assessed by determining whether the dental implant remains in situ and clinically functional without removal during the 6-month follow-up period.
Time frame: Up to 6 months after implant placement
Plan to share: No — Individual participant data (IPD) will not be shared because no formal data-sharing plan was included in the approved study protocol or informed consent. Study findings will be disseminated through scientific publication and presentation in aggregate form.
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Jun 2027, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.